Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Stock looking much better again.
One of their tweets below:
Learn more about Krillase: "a biochemical knife" that breaks down necrotic tissue and thrombogenic material that can mitigate or treat multiple disease states in humans.
http://marizyme.com/krillase/
$MRZM
Marizyme has gotten active on twitter over the last 4 days $MRZM
Yea tell me about it!
Waiting on $MZRM - need to see some sales #’s or something. Need something to post about.
Doesn't anyone ever come on this board anymore?
$MRZM NEWS! Marizyme, Inc., Appoints New Members to its Board of Directors
FORT COLLINS, Colo., Dec. 14, 2018 /PRNewswire/ -- Marizyme, Inc. ("Marizyme" or the "Company"), a publicly traded (OTC:MRZM) company focusing on acquiring late-stage drug assets for use in the acute care space for development and commercialization, announced today that it is appointing Mr. James Sapirstein and Mr. Terry Brostowin to the Board of Directors. In addition, the Company has accepted the resignation of Mr. Juan Francisco Gutierrez from the Board of Directors, for health reasons, and the resignation of Mr. Marco Nicolaides as the Company's Treasurer. The Company is very grateful to Mr. Gutierrez and Mr. Nicolaides for their service to the Company and their leadership during his term.
Mr. Sapirstein, who has been appointed Executive Chairman, is a highly-regarded pharmaceutical industry executive with more than 35 years of success in building companies and leading the commercial launch of nearly two dozen prescription drugs in the fields of CNS, infectious disease, and cancer. He has worked at major pharmaceutical companies including Bristol-Myers Squibb, Hoffmann-LaRoche and Eli Lilly, and has led commercial teams for successful biotech companies such as Gilead Sciences and Serono Laboratories. In recent years, Mr. Sapirstein has been the founding CEO of the following early-stage biotech companies - Tobira Therapeutics, Alliqua Therapeutics and most recently, Contravir Pharmaceuticals, where he defined and executed corporate strategy, raised significant capital, advanced drug development programs, and built shareholder value.
Mr. Brostowin, who has been appointed as a Director, is an accomplished attorney admitted to the Federal Court in both the Eastern and Southern districts of New York. He has extensive expertise in contracts, and commercial litigation. Mr. Brostowin has advised the New York City Mayor's office on judicial appointments and was a compliance specialist ensuring agencies followed court ordered activities and ensured the financial integrity of the Financial Systems Division accounting and budgetary systems. Mr. Brostowin has been affiliated with the law firm Brostowin & Associates, PC , since 2009. From 2002 to 2009, Mr. Brostowin was affiliated with the law firm Conway & Brostowin, LLC.
Mr. Handley commented, "We are excited to have James's leadership and deep biotechnology and public company experience on our Board. Terry's legal and compliance background is an excellent fit for us as well and we look forward to utilizing his capabilities. Together, these appointments bring the Company closer to its goal of becoming a leader in the field of acute care therapeutics."
About Marizyme, Inc.
Marizyme, Inc. is a development-stage company dedicated to the commercialization of therapies that address the urgent need relating to higher mortality and costs in the acute care space. Specifically, Marizyme will focus its efforts on developing treatments for disease caused by thrombus (stroke, acute myocardial infarctions, or AMIs, and deep vein thrombosis, or DVTs), infections and pain/neurological conditions. For more information about the Company, visit www.marizyme.com.
bought a few today. @ .49 - seems cheap compared to the below:
$14.5m was recently raised @ $2.13 a share. https://ih.advfn.com/p.php?pid=nmona&article=78273314
$MRZM
someone is not impressed with the 10q - lol - bid is down to .30
got me some $1.35's today - what the hey, it's only money - besides some other suckers recently bought @ $2.13 a share- spending $14.5m https://ih.advfn.com/p.php?pid=nmona&article=78273314 $MRZM
$1.6 pps bargain $MRZM pricing - $14.5m was recently raised @ $2.13 a share. https://ih.advfn.com/p.php?pid=nmona&article=78273314
looks good. $$$ $MRZM $$$
The company`s website has gone live now:
http://marizyme.com
$MRZM NEWS! Marizyme, Inc., Acquires Protease Drug Platform And Appoints New CEO
(MORE TO FOLLOW) Dow Jones Newswires (212-416-2800)
September 27, 2018 00:37 ET (04:37 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Press Release: Marizyme, Inc., Acquires Protease Drug Platform and Appoints New CEO
Marizyme, Inc., Acquires Protease Drug Platform and Appoints New CEO
- Company acquires first late-stage asset for development and commercialization in the acute care space -
PR Newswire
FORT COLLINS, Colo., Sept. 27, 2018
FORT COLLINS, Colo., Sept. 27, 2018 /PRNewswire/ -- Marizyme, Inc. ("Marizyme" or the "Company"), a publicly traded (OTC:MRZM) company focusing on acquiring late-stage drug assets for use in the acute care space for development and commercialization, announced today that they have acquired their first drug assets. Marizyme completed an Asset Purchase Agreement for a novel protease drug platform that has had extensive clinical testing in Europe. This protease platform is a novel combination of enzymes first isolated and developed by Pharmacia Corporation in Sweden. It has been tested in over 551 patients and has demonstrated safety and efficacy for multiple indications including wound healing, thrombogenic disease and anti-viral applications.
MB101, the Company's first product candidate based on this protease platform, is a patented, first-of-its-kind localized enzymatic therapy that is initially being developed for use as a therapy for wound debridement and healing. It has been successfully tested in Europe in 13 clinical trials involving 551 patients. The Company will be filing a Pre-IND with the Food & Drug Administration to request that MB101 can be used in a Phase IIb/III clinical study.
The Company's second product candidate based on this platform, MB102, is a novel and patented formulation of endovascularly delivered proteases that have demonstrated the capability to quickly and safely remove clots causing ischemic blockages in human vasculature. The first indication will be ischemic stroke in pediatrics as there are currently no approved thrombolytic therapies approved for use in children suffering from ischemic stroke.
In addition to acquiring the protease drug platform, Marizyme has hired a successful pharmaceutical professional to run the Company. Mr. Michael K. Handley has been hired as the Chief Executive Officer and Board member and will replace Mr. Nick DeVito. The Company is very grateful to Mr. DeVito for all of his efforts to position the Company for success. Mr. Handley brings over twenty years of pharmaceutical and device development and commercialization knowledge. He has led or assisted in the development multiple products to market for combined annual sales of over $3 billion dollars.
Mr. Handley, commented, "It is an honor to lead this Company into its next chapter of its growth. I am excited about the opportunity to develop one of the world-leading acute care focused companies and improve and save lives of patients who are afflicted from thrombogenic disease, infections or pain."
About Marizyme, Inc.
Marizyme, Inc. is a development-stage company dedicated to the commercialization of therapies that address the urgent need of higher mortality and costs in the acute care space. Specifically, Marizyme will focus its efforts on developing treatments for disease caused by thrombus (stroke, acute myocardial infarctions or AMI's and deep vein thrombosis or DVT's), infections and pain/neurological conditions. These conditions combine for over $95 billion dollars in potential market opportunity and are responsible for sending over 10 million patients to the hospital every year in the U.S. alone.
The Company's first products candidates are derived from a broad intellectual property portfolio around a novel system of proteolytic enzymes called ProteomeX(TM) (previously referred to as Krillase(TM) Technology). Marizyme completed the acquisition of these assets and intends to immediately develop several product candidates that will address unmet medical needs in the acute care setting. For more information about the Company, visit www.marizyme.com.
my guess is that buying any $MRZM @ $2.13 a share or less is money $$$:
https://ih.advfn.com/p.php?pid=nmona&article=78273314
good news. $14.5m raised on 6.8m shares- that's $2.13 a share. $$$ $MRZM $$$
https://ih.advfn.com/p.php?pid=nmona&article=78273314
On September 12, 2018, we consummated an acquisition with ACB Holding AB, Reg. No. 559119-5762, a Swedish corporation, to acquire all right, title and interest in their Krillase technology in exchange for 16.98 million unregistered shares of Common Stock, shares to be issued to certain individuals and entities set forth in the asset purchase agreement. Krillase is a naturally occurring enzyme that acts to break protein bonds and has applications in dental care, wound healing and thrombosis.
BOOM!:
Intellectual Property
We acquired patents and patent applications in biotechnology pursuant to that certain Asset Purchase Agreement, date September 12, 2018, between ACB Holding AB, Reg. No. 559119-5762, a Swedish corporation, and Marizyme, Inc.
We own the internet domain names, http://www.marizyme.com and http://www.marizymebiotech.com. The information contained in the Company’s websites is not incorporated by reference herein.
Good job figuring that out. would be nice to cash out on the x-asset shares one of these days. $$$ $MRZM $$$
From the recently published Information Statement we can now infer the value of the X-Asset stock. Based on an at-equity valuation, the NAV per X-Assets share is stated as USD 1.22 in the Information Statement. Based on a mark-to-market valuation the NAV is app. USD 0.90 per share which is exactly in line with my previos forecast.
Krillase®
Applications
A. Chronic Wound Care:
Chronic non-healing wounds require special care and often last many month and years or may never fully
heal. The increased prevalence of these types of wounds is caused by growth in diabetes and longer lifespans. Many of these wounds can result in amputation if treatments cannot control the growth of necrotic tissue. To treat these wounds often requires grafting which may not be effective if the wound isn’t properly cleansed of necrotic tissue prior to the graft. We estimate grafting is only successful about 35% of the time. Krillase makes grafting possible by achieving up to a 90% efficacy rate for the grafting process. Krillase has achieved Class III Medical Device classification.
Wound Care Monetization Strategy:
We expect to license this application of our technology first. Our partner expects to complete a facility and intends to sell directly to hospitals as part of their grafting programs. The hospitals are reimbursed $8,500 by the insurance companies for the entire grafting procedure and we expect to receive approximately $1,500 per procedure from the hospital leaving $7,000 for the hospital to cover their expenses, the doctors, and profit margins. Total market size in Germany could be as much as $6 Billion for Krillase as a result
B. Thrombolysis:
Krillase will completely dissolve the thrombus by breaking down the fibrins and can be applied in any timeframe. The proteolytic enzymes in Krillase can breakdown any fibrous cap on any age of clot. This is
extremely useful if the patient hasn’t been able to reach an acute care center within the required 3-6 hours for tPA and TNK. Also, Krillase works in 1/10th the time dissolving complex aged clots in 3 minutes as opposed to 30 minutes thus saving more heart or brain tissue from ischemic death. Most importantly, due to the mechanism of action of Krillase, there is no chance of bleed out and it would be acceptable to use it in most patient populations, even children.
Thrombolysis Monetization Strategy:
Marizyme intends to apply for a Rare Pediatric Voucher and
complete studies for application of Krillase in children. The Rare Pediatric Disease Voucher is transferable and of the 13 or so that have been issued most have been sold to large pharmaceutical companies for $125M to $350M. We intend to complete a pediatric stroke study and license Krillase to Roche/Genentech for human use and then sell the Voucher to the highest bidder.
3. Marizyme Business Model
Quote:
We intend to follow a model of licensing out our promising technologies for individual applications to larger players who bring competitive advantages that our shareholders will benefit from including distribution, industry certification, unique market experience, brand or assistance in completing clinical studies. We intend to grant exclusive licenses to our technology either worldwide or on a larger territory basis for specific applications. In exchange we will seek ownership in our partner when feasible, milestone payments, and ongoing royalties. Our partners will be expected to make investments in the final product
and to package, market and distribute that product. We believe this approach will allow us to pursue several opportunities concurrently and we will begin with the first three applications described within this summary.
whoever is needing to give themselves a headache read the below:
http://www.viewproxy.com/marizyme/2018/InformationStatement2018.pdf
or since i already have a headache from ready i can summarize what i understand it to be saying.
1) they had to separate the x-assets from $MRZM as part of the deal. (this part is over x-asset shares were issued 9.5.18)
2) going forward $MRZM they will have world wide licence to sell wound care product.
looks like we may get some money for our x-asset shares if they ever liquidate the holdings of the German company- GBS Software AG.
X-Assets is a holding company and has no operations. Its assets mainly consist of 1,198,324 shares of GBS Software AG
(“GROUP”), a German-based public-company whose stock trades on the Frankfurt Exchange under ISIN DE 000A14KR27/
WKN A14KR2, representing a minority interest in the outstanding GROUP shares as of the date of this Information Statement.
GROUP’s software and consulting business was focused on serving IBM’s Lotus Notes and Domino market. GROUP provided
IBM Lotus Notes/Domino Application and Transformation technology. Headquartered in Karlsruhe, Germany, GROUP had
offices throughout Europe and North America and maintained a website at www.gbs-ag.com. The information contained on
GROUP’s website is not incorporated by reference herein
Thanks for letting me know. I am still waiting for the X-assts shares to be booked.
.90 that would be sweet. thanks for the info. $$$ $MRZM $$$
Yes, sometimes reading does pay. The legacy assets consist almost entirely of shares in the parent company. I figure the value of one X-assets share could be as much as 0.90 USD provided there were no offsetting legacy liabilities.
thanks. i guess it pays to read the 10k's- i thought reading those were just good for getting head aches. do you know what kind of dollar value the legacy assets are worth?
$$$ $MRZM $$$
As stated previously in the 10 K, all legacy assets of the shell will be transferred to a newly established SPV, X-assets, whose shares are held by MRZM. Subsequently, X-assets shares will be distributed 1 for 1 to legacy shareholders - as of now all shareholders are legacy shareholders; this will only change once the capital increase by 15m new shares has been conducted.
Has anyone yet received the X-assets shares that were spun off as of August 21?
Good timing - today up by 25%
yep. 300 shares bought and didn't register on the L2- however- latter in the day 100 showed up on L@ as out of sequence- the other 200 shares i bought never registered on the L2. i don't know if others were buying that day - i bought 300 shares that day - and the total reported for the day was only 100.
looks like today everything is on the L2 but who really knows?
$$$ $MRZM $$$
Were those your orders?
yeppers. spin off sounds good to me, but no details - so who knows- market didn't react very well to the news. it would be nice to hear from the company one of these days LOL
Stock now went from 2.40 to 1 in less than 2 trading days since it showed up on the daily list yday in regards to a spin off. Weird.
Right on! Thanks buddy!
i have no idea. could be tomorrow or a year from tomorrow. the company doesn't even have their website up and running yet. http://marizyme.com/
When do you think this may occur?
there is a lot of unknown factors- particularly 1) revenue/profits/debt 2) final share structure - so $10 pps is just my best guess with the info i have on hand -> 1) current known share structure 2) potential revenue
if they are using toxic debt and generate no sales $MRZM could trade pennies
my guess right now is $10 plus pps - as more info becomes available then potential pps value will more easier to figure out
Do you think $10 PPS is realistic?
Looking for $10 plus PPS for $MRZM
my guess is $MRZM will not capture the entire Total market in Germany of $6 Billion for Krillase
if they were able to bank $6bil a year i would be looking for $300 PPS based on the estimations below:
after r/s - o/s is approximately 1m shares
Lots of times these companies only want legacy holders to own 5%
If the above holds true - the o/s would be 20m shares
Revenue of $6bil a year - with a 10% profit margin would = $600m yearly profit
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=142530837
$600m profit / 20m shares = $30 EPS
EPS x a factor of 10 = $300 pps
What’s the hold up. I’m ready. http://marizyme.com/ $MRZM
GBSXD symbol changed to MRZM
http://otce.finra.org/DailyList
Yep. Not here for beer $GBSXD
Followers
|
7
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
359
|
Created
|
02/17/11
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |